12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Company News  |  Deals

Amgen, DaVita Inc., Fresenius Medical Care AG & Co. KGaA deal

DaVita will purchase no less than 90% of the erythropoiesis-stimulating agents (ESAs) used by itself and its affiliates to provide dialysis services in the U.S. and Puerto Rico. Amgen will provide Epogen at an undisclosed discount, along with rebates. Some of the rebates are subject to conditions, including...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >